The largest database of trusted experimental protocols

547 protocols using d luciferin

1

Noninvasive Nasal Luciferase Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
For live animal imaging of nasal luciferase expression 16 (link), mice were anesthetized with isoflurane and D-luciferin (Gold Biotechnology, St Louis, MO, USA) substrate (20 μl of 25mg/ml D-luciferin in PBS) was delivered by intranasal administration 35 (link). Mice were imaged using the IVIS Lumina optical imaging system (Caliper Life Sciences, Hopkinton,MA, USA) and images of luciferase activity were collected using a charge-coupled device camera interfaced to a computer. Data is presented as the average ± S.E.M.in photons/sec/cm2.
+ Open protocol
+ Expand
2

Bioluminescence Imaging of Mice and Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
BLI was performed as previously described (9 (link)). In vivo imaging was performed on an IVIS100 or IVIS Lumina (PerkinElmer, Downers Grove, IL; Living Image 3.2, 1–60sec exposures, binning 4, 8 or, 16, FOV 15cm, f/stop1, open filter). Mice were injected intraperitoneally with D-luciferin (150mg/kg in PBS; Gold Biotechnology) and imaged 10 minutes later under isoflurane anesthesia (2% vaporized in O2). Animals were sacrificed immediately following whole body imaging and both hind limbs were isolated and imaged for 10 seconds ex vivo. For analysis, total photon flux (photons/sec) was measured from a fixed region of interest (ROIs) over the whole body or bones using Living Image 2.6 software.
In vitro live-cell bioluminescence imaging was performed on an IVIS 50 as previously described (31 (link)). Briefly, in vitro live-cell bioluminescence imaging was performed on an IVIS 50 (PerkinElmer; Living Image 4.3, 5min exposure, bin8, FOV12cm, f/stop1, open filter). D-luciferin (150mg/ml; Gold Biotechnology) was added to black-walled plates 10min prior to imaging. Total photon flux (photons/sec) was measured from fixed regions of interest (ROIs) over the plate or tumors using Living Image 2.6.
+ Open protocol
+ Expand
3

In Vivo Bioluminescence Imaging Protocols

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo bioluminescence imaging was performed on an IVIS 50 (PerkinElmer; Living Image 4.3.1), with exposures of 1 s to 1 min, binning 2–8, field of view 12.5 cm, f/stop 1, and open filter. D-Luciferin (150 mg/kg in PBS; Gold Biotechnology) was injected into the mice i.p. and imaged ventrally using isoflurane anesthesia (2% vaporized in O2). The total photon flux (photons/s) was measured from regions of interest using the Living Image 2.6 program.
Cells and mesenteries were imaged using the IVIS 50 with (PerkinElmer; Living Image 4.3.1) 1-s to 1-min exposure, bin 4–8, field of view 12 cm, f/stop 1, and open filter after addition of 150 µg/ml D-Luciferin (Gold Biotechnology). For analysis, a grid was placed over the plate, and total photon flux (photons/s) was measured using Living Image 2.6.
+ Open protocol
+ Expand
4

Bioluminescent Imaging of 4T1-Luc2-RFP Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bioluminescent imaging was performed before wounding (2 weeks post tumor inoculation at 12 weeks of age) and before euthanasia (3 weeks post wounding at ~15 weeks of age) using a highly sensitive, IVIS Spectrum in vivo imaging system (PerkinElmer). D‐luciferin (Gold Biotechnology) was prepared per manufacturer's instructions in Dulbecco's phosphate‐buffered saline (DPBS) and filter sterilized with a 0.2‐μm filter for a concentration of 15 mg/mL. For all in vivo imaging, D‐luciferin solution was intraperitoneally injected (150 mg/kg) in all mice. Mice were then anesthetized with 2% isoflurane prior and during imaging with IVIS spectrum. Bioluminescence of D‐luciferin carried 4T1‐Luc2‐RFP tumor cells was quantified using Living Image, in which regions of interest from displayed images were identified and quantified as the total flux which is the radiance (photons/sec) in each pixel summed or integrated over the ROI area.
+ Open protocol
+ Expand
5

Tracking Lung Metastasis: DSAB-HK Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
To target lung metastasis, 0.5 nmol DSAB-HK or DSAB was intravenously injected into 4T1-fLuc lung metastatic mice or normal BALB/c mice (n = 5 per group). At 1, 2, 4, and 8 h postinjection, mice were subjected to NIRF imaging using an IVIS small-animal imaging system. For bioluminescence imaging (BLI), mice received an intraperitoneal injection of 150 mg/kg D-luciferin (Gold BioTechnology, St Louis, MO), and then BLI was performed using the IVIS spectrum system 10 min after D-luciferin administration. After BLI, mice were sacrificed, and the lungs were harvested, placed on a black paper, and then scanned by NIRF imaging to determine the location of DSAB-HK or DSAB.
Following the last NIRF scan at 8 h postinjection, mice were sacrificed and the major organs/tissues of mice were dissected, weighed, and NIRF imaged ex vivo. The organ uptake of DSAB-HK and DSAB were calculated as the percent injected dose per gram (%ID/g) as previously described 26 (link).
+ Open protocol
+ Expand
6

Noninvasive Nasal Luciferase Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
For live animal imaging of nasal luciferase expression 16 (link), mice were anesthetized with isoflurane and D-luciferin (Gold Biotechnology, St Louis, MO, USA) substrate (20 μl of 25mg/ml D-luciferin in PBS) was delivered by intranasal administration 35 (link). Mice were imaged using the IVIS Lumina optical imaging system (Caliper Life Sciences, Hopkinton,MA, USA) and images of luciferase activity were collected using a charge-coupled device camera interfaced to a computer. Data is presented as the average ± S.E.M.in photons/sec/cm2.
+ Open protocol
+ Expand
7

In vivo and ex vivo bioluminescence imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vivo bioluminescence was detected as previously described using an optical imaging device (Ami-X, Spectral Instruments Imaging) [17 (link)]. To detect in vivo bioluminescence signal, mice were i.p. injected with D-luciferin (150 mg kg−1, Goldbio, St. Louis, MO, USA). Aura Software (Spectral Instruments Imaging, Version 2.2.1.1) was used for quantification. Also, ex vivo imaging, tissues were collected from the CIDEA reporter mice treated with D-luciferin (150 mg kg−1, Goldbio, St. Louis, MO, USA). During imaging, the isolated tissues were maintained in 12 well plates containing D-luciferin (300 μg/ml).
+ Open protocol
+ Expand
8

Bioluminescent Tumor Imaging in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
MSF cells were injected in to the flanks of FVB mice, two injections/mouse. Cells were injected at a concentration of 4 × 105 cells/injection in 100 μl of a 1:1 solution (DMEM:growth factor-reduced matrigel (Corning). For co-injection experiments using PDSC5 and MK16-Ras tumour lines, the MSFs (4 × 105/injection) were mixed before injection with either 1.5 × 105 PDSC5 cells or 100 MK16-Ras cells per injection. Tumour growth for the MK16-Ras line was monitored using calipers. On day 26, MK16-Ras tumours were isolated for histological analysis. For the PDSC5 tumour line, bioluminescence imaging was used to monitor growth with images taken on days 2 and 9 following injection.
Bioluminescence imaging was performed using an IVIS Lumina (PerkinElmer; Living Image 3.2, 5 min exposure, bin8, FOV12.5 cm, f/stop1, open filter)53 (link). Mice were injected intraperitoneally with D-luciferin (150 mg kg−1 in PBS; Gold Biotechnology) and imaged 10 min later under isoflurane anaesthesia (2% vaporised in O2).
In vitro live-cell bioluminescence imaging was performed on an IVIS 50 (PerkinElmer; Living Image 4.3, 5 min exposure, bin8, FOV12 cm, f/stop1, open filter). D-luciferin (150 mg ml−1; Gold Biotechnology) was added to black-walled plates 10 min before imaging. Total photon flux (photons sec−1) was measured from fixed regions of interest over the plate or tumours using Living Image 2.6.
+ Open protocol
+ Expand
9

Subcutaneous and Intrasplenic PDA Xenograft Models

Check if the same lab product or an alternative is used in the 5 most similar protocols
Subcutaneous injection model: One million luciferase-expressing PDAT cells were injected subcutaneously into the flanks of mice. 12 days after transplantation, animals were randomly assigned to the vehicle control group (0.5% carboxymethylcellulose, 0.1% Tween80 in ddH2O) or TEPP46 treatment group (50 mg kg−1). Animals were dosed twice a day by oral gavage for 7 days. Tumor volume was monitored by caliper measurements using the following formula: tumor volume [mm3] = (length [mm]) × (width [mm]) × (height [mm]) × (π/6). To monitor for potential metastasis, mice were subject to bioluminescent imaging using the IVIS spectrum (PerkinElmer Cat# 124262) after injection with 150 mg kg−1 D-Luciferin (Goldbio Cat# LUCK).
Intrasplenic injection model: 50,000 luciferase-expressing PDAT cells were injected into the spleen as described above, after which animals were randomly assigned to the vehicle control group (0.5% carboxymethylcellulose, 0.1% Tween80 in ddH2O) or TEPP46 treatment group (50 mg kg−1). Animals were dosed twice a day by oral gavage. Body weight and tumor burden were measured at enrollment and once a week throughout the course of the study. To monitor tumor burden in the liver, mice were subject to bioluminescent imaging using the IVIS spectrum (PerkinElmer Cat# 124262) after injection with 150 mg kg−1 D-Luciferin (Goldbio Cat# LUCK).
+ Open protocol
+ Expand
10

Orthotopic Xenograft Breast Cancer Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal studies were performed according to the guidelines established by the Institutional Animal Care and Use Committee (IACUC) at the Penn State College of Medicine. An orthotopic xenograft breast cancer model was generated by injecting 2.0×106 MDA-MB-231 cells into the inguinal mammary fat pad of female NOD SCID Gamma (NSG) mice, aged 6–8 weeks. Cells were injected in a 50:50 mixture of PBS and matrigel basement membrane matrix (Fisher Scientific; cat#CB-40234). Mice were imaged for luciferase expression on a weekly basis for 7 weeks via a Xenogen IVIS bioluminescent imager. Mice were injected with 5ul/gram body weight of 30mg/ml Luciferin-D (Gold Biotechnology, cat# LUCK-1G) in PBS, 5 minutes prior to imaging. Photon flux was calculated using region of interest (ROI) measurements of either the primary tumor site, or the ventral thoracic area for lung metastasis. Tumor volume was also measured using calipers and calculated as πLW2/6. At the experiment end point, mice were euthanized and tumor, lung, and liver tissue were harvested for ex vivo analysis and subsequent histology.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!